RxDoctor Payments Data

Bhuwan Poudyal, MD

Hematology & Oncology · Bel Air, MDNPI 1528311891

Payments from drug & device makers

$558in general payments, 2019–2025

Across 12 payments — averaging $46.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$160
  • Astellas Pharma US Inc$100
  • Seagen Inc.$95
  • Novartis$44
  • Johnson & Johnson$40
  • Daiichi Sankyo Inc.$28
  • plus $91 from 4 others

What the payments were for

  • Food & beverage$20336%
  • Education$35564%

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$558 in reported general payments places this provider in the 20th percentile of 242 hematology & oncology providers in Maryland.

See all hematology & oncology providers in Maryland

Medicare billing

Part B allowed, 2024
$833,156
Medicare patients
354
Services billed
29,255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Entecavir11$1,087
Prochlorperazine Maleate30$641
Ondansetron Hcl29$328
Anastrozole23$307
Dexamethasone12$265
Oxycodone Hcl12$158
Acyclovir14$114
Ibandronate Sodium11$100

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Bel Air

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →